Read More Pharma Industry News Drug Farm advances DF-003 into FDA rare disease evidence pathway as ROSAH syndrome program enters regulatory dialogue phase Drug Farm’s DF-003 enters the FDA Rare Disease Evidence Principles Process for ROSAH syndrome. Discover why this regulatory collaboration could shape rare disease drug development. bySrinathMarch 5, 2026